Chairman of the Board
Carl E. Berg is Co-Founder, Chairman of the Board and Principal Investor of BERG. Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. Carl has built or owned over 15 million sq. feet of commercial real estate., Mr. Berg was the Chairman of the Board and CEO of Mission West Properties, Inc. From 1997 until its sale in 2012. Mission West Properties was a public real estate investment trust with Microsoft & Apple as major tenants.
Co-founder, President & Chief Executive Officer
Niven R. Narain is Co-Founder, President, & CEO of BERG. His foremost passion is to improve healthcare systems and patient care through the fusion of AI and patient biology to develop the next generation of therapeutics. As CEO, Niven drives the vision of the translational engine from discovery to clinical development and ensures that BERG is collaborating with like-minded institutions to advance product development. He discovered Interrogative Biology®, BERG’s flagship platform that has created a robust pipeline of products in cancer, diabetes, and CNS diseases. BPM 31510 is BERG’s lead asset in solid tumors which is currently in Phase II trials. He is inventor on over 600 issued and pending patents over a diverse range of assets in drugs and diagnostics.
Jonathan Symonds, CBE, serves as a board advisor to BERG. He was appointed as an independent non-executive Director of HSBC Holdings plc in April 2014. He has extensive international financial and governance experience. Mr Symonds is Chairman of HSBC Bank plc, HSBC’s European subsidiary, which offers services to clients in the UK and Continental Europe. Mr Symonds was Chief Financial Officer of Novartis AG from 2009 to 2013. Before joining Novartis he was a Partner and Managing Director of Goldman Sachs; Chief Financial Officer of AstraZeneca plc; and a Partner at KPMG. His governance experience includes roles as non-executive Director and chair of the audit committees of Diageo plc and QinetiQ plc. He is currently Chairman of Innocoll AG and of Proteus Digital Health Inc. and a non-executive director of Genomics England Limited.
Shumeet Banerji serves on the board as the Audit Chairman for BERG. He is the founder of Condorcet, LP an advisory and investment firm specializing in developing early stage companies. Mr. Banerji retired from Booz & Company in 2013 after a 20 year career at the firm and its predecessor Booz, Allen, Hamilton. He was the founding Chief Executive Officer of Booz & Company. In 2007-8 he co-led the conception, design, and execution of the historic deal separating Booz, Allen & Hamilton, selling the government business to the Carlyle Group and spinning off the global strategy consulting division as Booz & Company. Mr. Banerji currently serves on the Board of Directors of HP Inc. (USA), Innocoll Holdings (Ireland), Reliance Jio Infocomm (India), Tala Energy (UK), Felix Pharmaceuticals (Ireland) and Proteus Digital Health (USA) and is Senior Advisor to Absolutdata (USA). He serves on the Panel of Senior Advisers of Chatham House (The Royal Institute of International Affairs, UK), the Advisory Board of One Mind (USA), and the Advisory Board of the Global Economic Symposium (Germany).
Major General Granger serves as a board director for BERG. He is currently the President and CEO of The 5Ps, LLC, a health care, education, and leadership consulting organization, Centennial, CO 80015 since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the Deputy Director and Program Executive Officer of the TRICARE Management Activity, Office of the Assistant Secretary of Defense (Health Affairs), Washington, DC, from December 2005 to May 2009. In this role, he was the principal advisor to the Assistant Secretary of Defense (Health Affairs) on DOD health plan policy and performance.
Eric J. Nestler serves as a board director for BERG. He is the Nash Family Professor of Neuroscience, Chairman of the Department of Neuroscience and Director of the Friedman Brain Institute at the Mount Sinai Medical Center in New York. His work in neuropsychopharmacology has been instrumental in forming a molecular approach to psychiatry and has furthered the understanding of the molecular basis of both depression and drug addiction, using animal models to study the way drug use or stress affects the brain. Dr. Nestler is the author of Neurobiology of Mental Illness and Molecular Neuropharmacology, and more than 400 chapters and peer-reviewed publications. He is active in six research projects funded by the National Institute on Drug Abuse and the National Institute of Mental Health.